

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Anderson et al.

Appl. No.: 08/

921,060

Series Code ↑

Serial No. ↑

Filed: August 29, 1997

Hon. Commissioner of Patents

Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER

Group Art Unit

1644

Examiner:

R. Schwadron

Atty. Dkt.

P

0275463

1992-30-0029CP2

M#

Client Ref

Appln. Title: Therapeutic Application of Chimeric and
Radiolabeled Antibodies to Human B
Lymphocyte Restricted Differentiation
Antigen for Treatment of B Cell
Lymphoma

Date: October 30, 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED**RECEIVED**

1. Small Entity claim A. <input checked="" type="checkbox"/> NOT made B. <input type="checkbox"/> Withdrawn C. <input type="checkbox"/> made herewith D. <input type="checkbox"/> made previously		For B & C See Required Separate Paper (Pat-256)		Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims				**minus	0	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims				***minus	0	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)							+ \$280/\$140 =	+ \$0	104/204
5. Original due Date:				<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached				(1 mo) (2 mos) (3 mos) (4 mos) (5 mos)	\$110/\$55 = \$400/\$200 = \$920/\$460 = \$1,440/\$720 = \$1,960/\$980 =	+ \$0		115/215 116/216 117/217 118/218 128/228	
7. Enter any previous extension fee paid since above original due date and subtract							- \$0		
8.							Extension Fee	+ \$0	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee							+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c), or if Rule 97(d) Request							+ \$180	+ \$0	126 126
11. After-Final Request Fee per rules 129(a) and 17(r)							+ \$740/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)							x \$740/370 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)							+ \$740/370	+ \$0	1179/1279
14. Petition fee for								+ \$0	
15.							TOTAL FEE =	\$	
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".							PLEASE CHARGE OUR DEP. ACCT		
17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.									
18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.									

Our Deposit Account No. 03-3975)

(Our Order No. 037003

C#

0275463

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Robin L. Teskin


Reg. No. 35,030

P.O. Box 10500

McLean, VA 22102

Tel: (703) 905-2000

Sig:



Fax:

(703) 905-2500

Tel:

(703) 905-2200

Atty/Sec: RLT/af

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments



RECEIVED
OCT 3 1 2002 461
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson et al.

Group Art Unit: 1644

Application No. 08/921,060

Examiner: R. Schwadron

Filed: August 29, 1997

Title: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA

* * * * *

PRELIMINARY AMENDMENT

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

Prior the examination add the following additional claims.

IN THE CLAIMS

23. A method of treating a human patient suffering from B cell lymphoma comprising administering a therapeutically effective amount of a non-radiolabeled chimeric anti-CD20 antibody, wherein said chimeric anti-CD20 antibody when administered by itself at a dosage of 0.4 mg/kg body weight results in nearly complete B cell depletion within about 24 hours post treatment infusion of said chimeric anti-CD20 antibody.

24. A method of inducing B cell depletion in a patient in need of such depletion comprising administering a B cell depleting effective amount of a non-radiolabeled chimeric anti-CD20 antibody, wherein said chimeric anti-CD20 antibody wherein administered by itself at a dosage of 0.4 mg/kg body weight results in merely complete B cell depletion within about 24 hour post treatment infusion of said chimeric anti-CD20 antibody.

25. The method of claim 11 wherein said chimeric anti-CD20 antibody contains the variable heavy sequence corresponding to SEQ ID NO: 11.

26. The method of claim 11 wherein said chimeric anti-CD20 antibody contains the variable light sequence corresponding to SEQ ID NO: 7.

27. The method of claim 16 wherein said chimeric anti-CD20 antibody contains the variable heavy sequence corresponding to SEQ ID NO: 11.